Soleno Therapeutics (SLNO) Gains from Investment Securities (2016 - 2019)
Historic Gains from Investment Securities for Soleno Therapeutics (SLNO) over the last 7 years, with Q4 2019 value amounting to $7.9 million.
- Soleno Therapeutics' Gains from Investment Securities rose 48116.85% to $7.9 million in Q4 2019 from the same period last year, while for Dec 2019 it was $7.0 million, marking a year-over-year increase of 47141.33%. This contributed to the annual value of $2.8 million for FY2024, which is 37487.44% up from last year.
- Soleno Therapeutics' Gains from Investment Securities amounted to $7.9 million in Q4 2019, which was up 48116.85% from -$7.1 million recorded in Q3 2019.
- Soleno Therapeutics' Gains from Investment Securities' 5-year high stood at $7.9 million during Q4 2019, with a 5-year trough of -$7.1 million in Q3 2019.
- Over the past 5 years, Soleno Therapeutics' median Gains from Investment Securities value was $50000.0 (recorded in 2016), while the average stood at $273182.9.
- Per our database at Business Quant, Soleno Therapeutics' Gains from Investment Securities crashed by 52265.31% in 2018 and then soared by 127730.06% in 2019.
- Over the past 5 years, Soleno Therapeutics' Gains from Investment Securities (Quarter) stood at $515860.0 in 2015, then plummeted by 432.67% to -$1.7 million in 2016, then skyrocketed by 128.55% to $490000.0 in 2017, then plummeted by 522.65% to -$2.1 million in 2018, then surged by 481.17% to $7.9 million in 2019.
- Its Gains from Investment Securities was $7.9 million in Q4 2019, compared to -$7.1 million in Q3 2019 and $4.3 million in Q2 2019.